Literature DB >> 32773429

Authors' response.

Pranab Chatterjee1, Tanu Anand2, Kh Jitenkumar Singh3, Reeta Rasaily4, Ravinder Singh5, Santasabuj Das6, Harpreet Singh7, Ira Praharaj8, Raman R Gangakhedkar8, Balram Bhargava9, Samiran Panda10.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32773429      PMCID: PMC7853284          DOI: 10.4103/0971-5916.291401

Source DB:  PubMed          Journal:  Indian J Med Res        ISSN: 0971-5916            Impact factor:   2.375


× No keyword cloud information.
We thank Kunte et al1 for a critical reading of our article2 and expressing their appreciation for our work on the prophylactic use of hydroxychloroquine (HCQ) in healthcare workers (HCWs). The authors1 found our study design to be suitable and the issues we covered while exploring factors associated with SARS-CoV-2 infection in HCWs appropriate. It also did not escape the notice of the authors of the letter1 that we had underscored the importance of use of personal protective equipment, as a preventive strategy in conjunction with HCQ. The lower response rate in our study, as has been pointed out, is a known limitation of a telephone-based survey method. It has been seen that while face-to-face surveys are able to cover wider grounds and attain greater representativeness, telephone surveys may need to approach a larger sample of population to compensate for non-participation. However, telephone-based surveys perform better compared to online, mail, or self-reported data collection methods34. We tried to maximize the response rates by reaching out to non-responders by calling them over the phone two additional times, preferably at a different time than the previous call. Worth noting was that the response rates (61% in cases and 68% in controls) in our study were higher compared to the rates encountered in other studies that engaged HCWs in India (paediatricians: 57%)5, Germany (physicians: 56%)6, France (physicians: 59%)7 and the USA (internists: 64%)8. Our study did not seek to establish the difference in clinical severity of COVID-19 between HCWs taking HCQ prophylaxis and those not taking it. Answering this question would require a differently designed investigation. We find the authors’ proposition of a built-up period of HCQ administration before engaging in clinical care of COVID-19 patients interesting. However, this would need to be based on the data generated through prospective HCQ prophylaxis study. We found associations through case-control investigation, which were indicative of the prophylactic effect of HCQ, and highlighted the need for clinical trials as also suggested by Kunte et al1.
  5 in total

1.  Doctors' opinions on euthanasia, end of life care, and doctor-patient communication: telephone survey in France.

Authors:  P Peretti-Watel; M K Bendiane; H Pegliasco; J M Lapiana; R Favre; A Galinier; J P Moatti
Journal:  BMJ       Date:  2003-09-13

2.  A national survey of U.S. internists' experiences with ethical dilemmas and ethics consultation.

Authors:  Gordon DuVal; Brian Clarridge; Gary Gensler; Marion Danis
Journal:  J Gen Intern Med       Date:  2004-03       Impact factor: 5.128

3.  Subjective Reasons for Non-Reporting of Adverse Drug Reactions in a Sample of Physicians in Outpatient Care.

Authors:  M Gahr; J Eller; B J Connemann; C Schönfeldt-Lecuona
Journal:  Pharmacopsychiatry       Date:  2016-01-07       Impact factor: 5.788

4.  Healthcare workers & SARS-CoV-2 infection in India: A case-control investigation in the time of COVID-19.

Authors:  Pranab Chatterjee; Tanu Anand; Kh Jitenkumar Singh; Reeta Rasaily; Ravinder Singh; Santasabuj Das; Harpreet Singh; Ira Praharaj; Raman R Gangakhedkar; Balram Bhargava; Samiran Panda
Journal:  Indian J Med Res       Date:  2020-05       Impact factor: 2.375

5.  Prophylactic use of hydroxychloroquine among healthcare workers in a case-control study.

Authors:  Renuka Kunte; Arun Kumar Yadav; Dharamjeet Singh Faujdar; Rajesh Sahu; Dashrath Basannar; Seema Patrikar; Kunal Chatterjee; R M Gupta; Nardeep Naithani
Journal:  Indian J Med Res       Date:  2020 Jul & Aug       Impact factor: 2.375

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.